Influenza vaccination in the elderly boosts antibodies against conserved viral proteins and egg-produced glycans.
Adult
Age Factors
Aged
Animals
Antibodies, Monoclonal
/ immunology
Antibodies, Viral
/ biosynthesis
Cohort Studies
Cross Reactions
Eggs
/ analysis
Humans
Immunoglobulin G
/ biosynthesis
Influenza A Virus, H1N1 Subtype
/ immunology
Influenza A Virus, H3N2 Subtype
/ immunology
Influenza Vaccines
/ immunology
Influenza, Human
/ immunology
Middle Aged
Polysaccharides
/ immunology
Vaccination
Viral Proteins
/ immunology
Adaptive immunity
Infectious disease
Influenza
Vaccines
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
received:
16
02
2021
accepted:
19
05
2021
entrez:
1
7
2021
pubmed:
2
7
2021
medline:
14
10
2021
Statut:
ppublish
Résumé
Seasonal influenza vaccination elicits a diminished adaptive immune response in the elderly, and the mechanisms of immunosenescence are not fully understood. Using Ig-Seq, we found a marked increase with age in the prevalence of cross-reactive (CR) serum antibodies that recognize both the H1N1 (vaccine-H1) and H3N2 (vaccine-H3) components of an egg-produced split influenza vaccine. CR antibodies accounted for 73% ± 18% of the serum vaccine responses in a cohort of elderly donors, 65% ± 15% in late middle-aged donors, and only 13% ± 5% in persons under 35 years of age. The antibody response to non-HA antigens was boosted by vaccination. Recombinant expression of 19 vaccine-H1+H3 CR serum monoclonal antibodies (s-mAbs) revealed that they predominantly bound to non-HA influenza proteins. A sizable fraction of vaccine-H1+H3 CR s-mAbs recognized with high affinity the sulfated glycans, in particular sulfated type 2 N-acetyllactosamine (Galβ1-4GalNAcβ), which is found on egg-produced proteins and thus unlikely to contribute to protection against influenza infection in humans. Antibodies against sulfated glycans in egg-produced vaccine had been identified in animals but were not previously characterized in humans. Collectively, our results provide a quantitative basis for how repeated exposure to split influenza vaccine correlates with unintended focusing of serum antibody responses to non-HA antigens that may result in suboptimal immunity against influenza.
Identifiants
pubmed: 34196304
pii: e148763
doi: 10.1172/JCI148763
pmc: PMC8245176
doi:
pii:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Viral
0
Immunoglobulin G
0
Influenza Vaccines
0
Polysaccharides
0
Viral Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : P01 AI089618
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM113132
Pays : United States
Organisme : NIGMS NIH HHS
ID : R24 GM137763
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
J Gen Virol. 1978 Nov;41(2):283-93
pubmed: 152802
Clin Immunol. 2018 Aug;193:70-79
pubmed: 29410330
Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W503-8
pubmed: 18503082
MMWR Morb Mortal Wkly Rep. 2020 Feb 21;69(7):177-182
pubmed: 32078591
J Virol. 2016 Sep 29;90(20):9383-93
pubmed: 27512055
Clin Infect Dis. 2012 Jul;55(1):19-25
pubmed: 22441650
Vaccine. 2010 Nov 29;28(51):8077-84
pubmed: 20974306
Cell Host Microbe. 2019 Mar 13;25(3):367-376.e5
pubmed: 30795981
Arch Virol. 2009;154(10):1599-604
pubmed: 19672555
Sci Transl Med. 2020 Dec 9;12(573):
pubmed: 33298562
Science. 2019 Oct 25;366(6464):499-504
pubmed: 31649200
Nucleic Acids Res. 2012 Sep 1;40(17):e134
pubmed: 22641856
Cell Rep. 2020 Jan 21;30(3):905-913.e6
pubmed: 31968262
Vaccine. 2006 Feb 20;24(8):1159-69
pubmed: 16213065
Viruses. 2018 Sep 13;10(9):
pubmed: 30217093
PLoS Pathog. 2012 Sep;8(9):e1002920
pubmed: 23028320
Elife. 2019 Aug 27;8:
pubmed: 31452511
Bull World Health Organ. 1969;41(3):643-5
pubmed: 5309489
Biochem J. 1998 Feb 1;329 ( Pt 3):511-8
pubmed: 9445377
Methods Enzymol. 2010;480:417-44
pubmed: 20816220
BMC Med Res Methodol. 2010 Mar 08;10:18
pubmed: 20210985
EBioMedicine. 2016 Jun;8:277-290
pubmed: 27428437
F1000Res. 2016 Mar 31;5:
pubmed: 27092249
Cell Host Microbe. 2014 Jul 9;16(1):105-14
pubmed: 24981332
J Immunol. 2011 Apr 1;186(7):4331-9
pubmed: 21357542
J Infect Dis. 2017 Mar 1;215(5):818-823
pubmed: 28011910
Immun Ageing. 2019 Sep 13;16:25
pubmed: 31528180
Virology. 1983 Apr 15;126(1):370-5
pubmed: 6189288
Anal Chem. 2014 May 20;86(10):4758-66
pubmed: 24684310
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Virology. 1981 Jan 15;108(1):71-9
pubmed: 6168095
Acta Naturae. 2019 Oct-Dec;11(4):22-32
pubmed: 31993232
J Infect Dis. 2014 Apr 1;209(7):986-94
pubmed: 24325965
PLoS One. 2012;7(4):e35497
pubmed: 22558161
Cell Host Microbe. 2019 Dec 11;26(6):715-728.e8
pubmed: 31757769
Nat Med. 2016 Dec;22(12):1465-1469
pubmed: 27820604
J Clin Invest. 2011 Aug;121(8):3109-19
pubmed: 21785218
N Engl J Med. 2010 Nov 18;363(21):2036-44
pubmed: 21083388
Nat Rev Dis Primers. 2018 Jun 28;4(1):3
pubmed: 29955068
Semin Immunol. 2018 Dec;40:83-94
pubmed: 30501873
PLoS One. 2017 Nov 1;12(11):e0185666
pubmed: 29091724
Nature. 2019 Feb;566(7744):398-402
pubmed: 30760926
Science. 2016 Jun 24;352(6293):1590-3
pubmed: 27339990
Nat Med. 2016 Dec;22(12):1456-1464
pubmed: 27820605
Nat Med. 2015 Jan;21(1):86-91
pubmed: 25501908
J Infect Dis. 2015 Apr 1;211(7):1038-44
pubmed: 25281755
NPJ Vaccines. 2020 Jan 10;5(1):3
pubmed: 31934357
Cell. 2016 Jul 28;166(3):609-623
pubmed: 27453470
Nat Commun. 2014 Sep 16;5:4816
pubmed: 25226414
J Infect Dis. 2015 Apr 1;211(7):1051-9
pubmed: 25336731
Annu Rev Pathol. 2008;3:499-522
pubmed: 18039138
Eur J Immunol. 1975 Oct;5(10):720-5
pubmed: 11993341
Vaccine. 2013 Aug 2;31(35):3603-10
pubmed: 23711934
Science. 2011 Aug 12;333(6044):850-6
pubmed: 21798894
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1105-1110
pubmed: 28096374
J Virol. 2011 May;85(10):5027-35
pubmed: 21367900
Front Immunol. 2019 Jul 18;10:1677
pubmed: 31379866
PLoS One. 2015 Apr 27;10(4):e0124677
pubmed: 25915748
Bioinformatics. 2015 Oct 15;31(20):3356-8
pubmed: 26069265
Cell. 2018 Apr 5;173(2):417-429.e10
pubmed: 29625056
PLoS One. 2011;6(10):e25797
pubmed: 22039424
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2259-64
pubmed: 24469811
Nature. 2014 Dec 18;516(7531):418-22
pubmed: 25296253
Sci Transl Med. 2013 Feb 6;5(171):171ra19
pubmed: 23390249
Microbiol Rev. 1992 Mar;56(1):152-79
pubmed: 1579108
Anal Chem. 2019 Apr 16;91(8):5083-5090
pubmed: 30908021
Nature. 2019 Feb;566(7744):393-397
pubmed: 30664748
Nat Immunol. 2006 May;7(5):449-55
pubmed: 16622432
Vaccines (Basel). 2018 Mar 26;6(2):
pubmed: 29587436
J Virol. 2020 Feb 28;94(6):
pubmed: 31826999
Proc Natl Acad Sci U S A. 1985 Mar;82(6):1785-9
pubmed: 3872457
Cell Immunol. 2020 Feb;348:103998
pubmed: 31733824
Nat Rev Immunol. 2019 Jun;19(6):383-397
pubmed: 30837674
Immunity. 2019 Jun 18;50(6):1530-1541.e8
pubmed: 31216462
Clin Immunol. 2018 Feb;187:37-45
pubmed: 29031828
Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12658-63
pubmed: 20615945
Vaccine. 2017 Feb 1;35(5):713-715
pubmed: 28065476
Virus Res. 2004 Jul;103(1-2):133-8
pubmed: 15163501
Glycoconj J. 2009 May;26(4):433-43
pubmed: 18853253
Nat Protoc. 2016 Mar;11(3):429-42
pubmed: 26844430
Cell Host Microbe. 2019 Mar 13;25(3):357-366.e6
pubmed: 30795982
Curr Opin Chem Biol. 2015 Feb;24:112-20
pubmed: 25461729
J Virol. 2015 Nov;89(22):11275-83
pubmed: 26311880